PT  - JOURNAL ARTICLE
AU  - Jonas Christoffer Lindstrøm
AU  - Solveig Engebretsen
AU  - Anja Bråthen Kristoffersen
AU  - Gunnar Øyvind Isaksson Rø
AU  - Alfonso Diz-Lois Palomares
AU  - Kenth Engø-Monsen
AU  - Elisabeth Henie Madslien
AU  - Frode Forland
AU  - Karin Maria Nygård
AU  - Frode Hagen
AU  - Gunnar Gantzel
AU  - Ottar Wiklund
AU  - Arnoldo Frigessi
AU  - Birgitte Freiesleben de Blasio
TI  - Increased transmissibility of the B.1.1.7 SARS-CoV-2 variant: Evidence from contact tracing data in Oslo, January to February 2021
AID  - 10.1101/2021.03.29.21254122
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.29.21254122
4099  - http://medrxiv.org/content/early/2021/03/30/2021.03.29.21254122.short
4100  - http://medrxiv.org/content/early/2021/03/30/2021.03.29.21254122.full
AB  - We use data from contact tracing in Oslo, Norway, to estimate the new SARS-CoV-2 B.1.1.7 lineage’s relative transmissibility. Within households, we find an increase in the secondary attack rate by 60% (20% 114%) compared to other variants. In general, we find a significant increase in the estimated reproduction number of 24% (95% CI 0% - 52%), or an absolute increase of 0.19 compared to other variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Norwegian Research Council, project no. 312721 and 237718 and by Nordforsk project no. 105572.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The contact tracing data analysis was done following the data processor agreement between the Norwegian Institute of Public Health and Oslo Municipality, fulfilling Article 28 no. 3 of the EU regulation 2016/679 (GDPR) of 27 April 2016 and the Act on the processing of personal data of 15 June 2018 no. 38 and associated regulations (Privacy Regulations). The study concerns national health preparedness, and the role of the Norwegian Institute of Public Health is specified in the Health Preparedness Act and the Infection Control Act.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is person sensitive and cannot be shared publically.